Equities Analysts Set Expectations for Qiagen Q3 Earnings

Qiagen (NYSE:QGEN) – Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Qiagen in a research report issued to clients and investors on Thursday, April 24th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.57 for the quarter, down from their previous forecast of $0.58. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%.

Several other brokerages have also issued reports on QGEN. Redburn Atlantic lowered shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. UBS Group dropped their price target on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Robert W. Baird boosted their price objective on Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Morgan Stanley reiterated an “equal weight” rating and set a $46.67 price target (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Finally, Baird R W lowered shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $47.83.

Qiagen Stock Performance

NYSE QGEN opened at $42.10 on Monday. The stock has a market capitalization of $9.36 billion, a price-to-earnings ratio of 117.23, a PEG ratio of 2.39 and a beta of 0.62. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30. The stock has a 50-day moving average of $39.95 and a 200 day moving average of $41.71. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC grew its stake in shares of Qiagen by 170.6% during the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after purchasing an additional 1,165,594 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Qiagen in the third quarter valued at approximately $53,000. Tidal Investments LLC purchased a new position in Qiagen in the third quarter valued at approximately $490,000. JPMorgan Chase & Co. increased its stake in Qiagen by 36.0% in the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock valued at $73,096,000 after purchasing an additional 424,937 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Qiagen by 170.1% during the fourth quarter. GAMMA Investing LLC now owns 1,518 shares of the company’s stock worth $68,000 after purchasing an additional 956 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.